TABLE 2.
Summary of type 2 diabetes variants in 2,598 control subjects and 2,309 case subjects from the Dundee cohort
| SNP | Gene/region | Risk allele frequency | Additive model test P value | OR (95% CI) | P value |
|---|---|---|---|---|---|
| rs7903146 | TCF7L2 | 0.30 | 0.70 | 1.36 (1.24–1.48) | 3.97 × 10−12 |
| rs5219 | KCNJ11 | 0.36 | 0.058 | 1.25 (1.15–1.36) | 8.54 × 10−8 |
| rs10811661 | CDKN2A/2B | 0.85 | 0.24 | 1.21 (1.08–1.35) | 8.82 × 10−4 |
| rs1801282 | PPARG | 0.87 | 0.46 | 1.21 (1.07–1.36) | 2.18 × 10−3 |
| rs2641348* | ADAM30/NOTCH2 | 0.11 | 0.68 | 1.15 (1.01–1.30) | 3.20 × 10−2 |
| rs564398 | CDKN2A/2B | 0.59 | 0.95 | 1.13 (1.04–1.22) | 3.61 × 10−3 |
| rs4402960 | IGF2BP2 | 0.33 | 0.76 | 1.12 (1.03–1.22) | 7.62 × 10−3 |
| rs8050136 | FTO | 0.41 | 0.32 | 1.11 (1.02–1.20) | 1.43 × 10−2 |
| rs10946398 | CDKAL1 | 0.34 | 0.19 | 1.11 (1.02–1.21) | 1.47 × 10−2 |
| rs13266634 | SLC30A8 | 0.70 | 0.60 | 1.10 (1.01–1.20) | 2.57 × 10−2 |
| rs7961581 | TSPAN8/LGR5 | 0.29 | 0.87 | 1.09 (1.00–1.19) | 5.56 × 10−2 |
| rs12779790 | CDC123 | 0.20 | 0.15 | 1.10 (0.99–1.21) | 7.58 × 10−2 |
| rs10010131 | WFS1 | 0.60 | 0.54 | 1.07 (0.99–1.16) | 9.19 × 10−2 |
| rs757210 | TCF2 | 0.37 | 0.18 | 1.07 (0.99–1.16) | 1.09 × 10−1 |
| rs4607103 | ADAMTS9 | 0.77 | 0.60 | 1.05 (0.96–1.16) | 2.89 × 10−1 |
| rs1111875 | HHEX-IDE | 0.62 | 0.19 | 1.02 (0.94–1.11) | 5.98 × 10−1 |
| rs7578597 | THADA | 0.91 | 0.33 | 1.04 (0.90–1.19) | 6.07 × 10−1 |
| rs864745 | JAZF1 | 0.50 | 0.50 | 1.00 (0.93–1.09) | 9.70 × 10−1 |
Only samples that were successfully genotyped for all 18 variants are included. Additive model test P value refers to a test of deviation from additivity of alleles at each SNP.
*
This SNP falls within the ADAM30 gene and is a proxy (r2 = 0.92 in HapMap CEU) for rs2934381 in the NOTCH2 gene, which showed stronger association previously (5).